Patents by Inventor Paul H. Bessette
Paul H. Bessette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230183308Abstract: A proprotein containing a functional protein coupled to a peptide mask that inhibits binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask.Type: ApplicationFiled: December 19, 2022Publication date: June 15, 2023Applicant: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason G. Sagert
-
Publication number: 20230035290Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.Type: ApplicationFiled: March 21, 2022Publication date: February 2, 2023Applicant: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason G. Sagert
-
Publication number: 20220119802Abstract: Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.Type: ApplicationFiled: June 25, 2021Publication date: April 21, 2022Inventors: Patrick S. Daugherty, Paul H. Bessette, Jeffrey Rice
-
Patent number: 11078479Abstract: Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.Type: GrantFiled: December 11, 2019Date of Patent: August 3, 2021Assignee: The Regents of the University of CaliforniaInventors: Patrick S. Daugherty, Paul H. Bessette, Jeffrey Rice
-
Publication number: 20200318099Abstract: Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.Type: ApplicationFiled: December 11, 2019Publication date: October 8, 2020Inventors: Patrick S. Daugherty, Paul H. Bessette, Jeffrey Rice
-
Publication number: 20200308243Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.Type: ApplicationFiled: November 11, 2019Publication date: October 1, 2020Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason G. Sagert
-
Patent number: 10544410Abstract: Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.Type: GrantFiled: June 11, 2018Date of Patent: January 28, 2020Assignee: The Regents of the University of CaliforniaInventors: Patrick S. Daugherty, Paul H. Bessette, Jeffrey Rice
-
Patent number: 10513549Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.Type: GrantFiled: May 8, 2017Date of Patent: December 24, 2019Assignee: CytomX Therapeutics, Inc.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason G Sagert
-
Publication number: 20190264194Abstract: Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.Type: ApplicationFiled: June 11, 2018Publication date: August 29, 2019Inventors: Patrick S. Daugherty, Paul H. Bessette, Jeffrey Rice
-
Patent number: 10301380Abstract: This invention relates generally to the generation of antibodies, e.g., monoclonal antibodies including fully human monoclonal antibodies, that recognize Jagged 1 and/or Jagged 2, to antibodies, e.g., monoclonal antibodies including fully human antibodies that recognize Jagged 1 and/or Jagged 2, and nucleic acid molecules that encode antibodies, e.g., nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both Jagged 1 and Jagged 2, and to methods of making the anti-Jagged antibodies and methods of using the anti-Jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically bind to Jagged 1 and Jagged 2, and to methods of making and using these activatable anti-Jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: June 23, 2017Date of Patent: May 28, 2019Assignee: CytomX Therapeutics, Inc.Inventors: James William West, Jason Gary Sagert, Paul H. Bessette, Henry Bernard Lowman, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
-
Patent number: 10041063Abstract: Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.Type: GrantFiled: August 7, 2015Date of Patent: August 7, 2018Assignee: The Regents of the University of CaliforniaInventors: Patrick S. Daugherty, Paul H. Bessette, Jeffrey Rice
-
Publication number: 20170298125Abstract: This invention relates generally to the generation of antibodies, e.g., monoclonal antibodies including fully human monoclonal antibodies, that recognize Jagged 1 and/or Jagged 2, to antibodies, e.g., monoclonal antibodies including fully human antibodies that recognize Jagged 1 and/or Jagged 2, and nucleic acid molecules that encode antibodies, e.g., nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both Jagged 1 and Jagged 2, and to methods of making the anti-Jagged antibodies and methods of using the anti-Jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically bind to Jagged 1 and Jagged 2, and to methods of making and using these activatable anti-Jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: June 23, 2017Publication date: October 19, 2017Inventors: James William West, Jason Gary Sagert, Paul H. Bessette, Henry Bernard Lowman, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
-
Publication number: 20170240608Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.Type: ApplicationFiled: May 8, 2017Publication date: August 24, 2017Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason G. Sagert
-
Patent number: 9688748Abstract: This invention relates generally to the generation of antibodies, e.g., monoclonal antibodies including fully human monoclonal antibodies, that recognize Jagged 1 and/or Jagged 2, to antibodies, e.g., monoclonal antibodies including fully human antibodies that recognize Jagged 1 and/or Jagged 2, and nucleic acid molecules that encode antibodies, e.g., nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both Jagged 1 and Jagged 2, and to methods of making the anti-Jagged antibodies and methods of using the anti-Jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically bind to Jagged 1 and Jagged 2, and to methods of making and using these activatable anti-Jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: July 31, 2015Date of Patent: June 27, 2017Assignee: CYTOMX THERAPEUTICS, INC.Inventors: James William West, Jason Gary Sagert, Paul H. Bessette, Henry Bernard Lowman, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
-
Patent number: 9644016Abstract: The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics.Type: GrantFiled: March 30, 2015Date of Patent: May 9, 2017Assignee: CYTOMX THERAPEUTICS, INC.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Jason G. Sagert
-
Patent number: 9453078Abstract: The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolyzed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolyzing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.Type: GrantFiled: September 26, 2013Date of Patent: September 27, 2016Assignee: CYTOMX THERAPEUTICS, INC.Inventors: Nancy E. Stagliano, James W. West, Kathryn Kamath, Paul H. Bessette, Fred Gluck, Jason Sagert, Patrick Daugherty
-
Publication number: 20160200826Abstract: This invention relates generally to the generation of antibodies, e.g., monoclonal antibodies including fully human monoclonal antibodies, that recognize Jagged 1 and/or Jagged 2, to antibodies, e.g., monoclonal antibodies including fully human antibodies that recognize Jagged 1 and/or Jagged 2, and nucleic acid molecules that encode antibodies, e.g., nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both Jagged 1 and Jagged 2, and to methods of making the anti-Jagged antibodies and methods of using the anti-Jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically bind to Jagged 1 and Jagged 2, and to methods of making and using these activatable anti-Jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: ApplicationFiled: July 31, 2015Publication date: July 14, 2016Inventors: James William West, Jason Gary Sagert, Paul H. Bessette, Henry Bernard Lowman, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary Menendez
-
Publication number: 20160032279Abstract: Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.Type: ApplicationFiled: August 7, 2015Publication date: February 4, 2016Inventors: Patrick S. Daugherty, Paul H. Bessette, Jeffrey Rice
-
Patent number: 9134309Abstract: Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.Type: GrantFiled: December 20, 2012Date of Patent: September 15, 2015Assignee: The Regents of the University of CaliforniaInventors: Patrick S. Daugherty, Paul H. Bessette, Jeffrey Rice
-
Patent number: 9127053Abstract: This invention relates generally to the generation of antibodies, e.g., monoclonal antibodies including fully human monoclonal antibodies, that recognize Jagged 1 and/or Jagged 2, to antibodies, e.g., monoclonal antibodies including fully human antibodies that recognize Jagged 1 and/or Jagged 2, and nucleic acid molecules that encode antibodies, e.g., nucleic acid molecules that encode monoclonal antibodies including fully human cross-reactive antibodies that recognize both Jagged 1 and Jagged 2, and to methods of making the anti-Jagged antibodies and methods of using the anti-Jagged antibodies as therapeutics, prophylactics, and diagnostics. The invention also relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically bind to Jagged 1 and Jagged 2, and to methods of making and using these activatable anti-Jagged antibodies in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: June 21, 2013Date of Patent: September 8, 2015Assignee: CYTOMX THERAPEUTICS, INC.Inventors: James William West, Jason Gary Sagert, Paul H. Bessette, Henry Bernard Lowman, Nancy E. Stagliano, Olga Vasiljeva, Elizabeth-Edna Mary Menendez